英文摘要 |
Objectives: A clinical manifestation of rheumatic disease is chronic inflammation that may increase the risk of cancer. The purpose of this study was to explore the risk of cancer and the precancerous medical utilization by children with rheumatism in Taiwan. Methods: This was a retrospective study with secondary data analysis. The data were drawn from the National Health Insurance Research Database from 2000 to 2012. Patients under the age of 18 with a diagnosis of pediatric rheumatic disease, including systemic lupus erythematosus, juvenile idiopathic arthritis, Sjögren’s syndrome, scleroderma, polymyositis, dermatomyositis, vasculitis and Behçet’s disease. A total of 1,741 cases were identified. The Cox proportional hazards model was used to analyze the risk of cancer, and the Mann-Whitney U Test was used to assess whether the patient’s medical use was different from that in the year prior to the diagnosis of cancer. Results: The overall risk for children with rheumatism compared with non-rheumatic patients was 3.71 times the risk for cancer; for systemic lupus erythematosus, juvenile idiopathic arthritis and Sjögren’s syndrome, the cancer risk was 3.94 times, 5.93 times and 5.29 times, respectively. The risk for cancer was increased by 5.65 times in those who had used immunoregulatory drugs, and this was 26.01 times more than that of those who had used biological agents. For children with rheumatism, in the year before the diagnosis of cancer and in terms of overall medical use before cancer, the number of outpatient visits and expenses increased, but the number of hospitalizations, hospital days, and cost reduction were not significantly different. Conclusions: Based on the results of this study, we suggest that the health authorities pay more attention to the medical care of children with rheumatism in order to avoid future social costs. |